{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gohari S"],"funding":["Dr. Abidi Pharmaceutical Company","Zanjan University of Medical Sciences"],"pagination":["170"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9669535"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(1)"],"pubmed_abstract":["Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet function, oxidant and antioxidant biomarkers and pro-inflammatory agents at baseline and at 26 weeks were measured. A total of 95 patients (41.05% male, mean age 62.85 ± 7.91 years, mean HbA<sub>1c</sub> 7.89 ± 0.96%) with concomitant T2DM and coronary artery disease (CAD) were randomized (1:1) to receive empagliflozin (10 mg/daily) or placebo. Patients treated with empagliflozin had lower levels of interleukin 6 (IL-6) (adjusted difference (adiff): - 1.06 pg/mL, 95% CI - 1.80; - 0.32, P = 0.006), interleukin 1β (IL-1β) and high-sensitive C-reactive"],"journal":["Diabetology & metabolic syndrome"],"pubmed_title":["The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial."],"pmcid":["PMC9669535"],"funding_grant_id":["1602001000"],"pubmed_authors":["Gohari S","Karbalaee-Hasani A","Arsang-Jang S","Mahmoodian R","Ghanbari S","Reshadmanesh T","Ismail-Beigi F","Mahjani M","Ahangar H","Fathi M","Asgari A","Muhammadi MJ","Taheri H","Khodabandehloo H","Moharrami M","Chiti H","Ghobadian B","Tayaranian M","Dadashi M"],"additional_accession":[]},"is_claimable":false,"name":"The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial.","description":"Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet function, oxidant and antioxidant biomarkers and pro-inflammatory agents at baseline and at 26 weeks were measured. A total of 95 patients (41.05% male, mean age 62.85 ± 7.91 years, mean HbA<sub>1c</sub> 7.89 ± 0.96%) with concomitant T2DM and coronary artery disease (CAD) were randomized (1:1) to receive empagliflozin (10 mg/daily) or placebo. Patients treated with empagliflozin had lower levels of interleukin 6 (IL-6) (adjusted difference (adiff): - 1.06 pg/mL, 95% CI - 1.80; - 0.32, P = 0.006), interleukin 1β (IL-1β) and high-sensitive C-reactive","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T06:16:00.259Z","creation":"2024-11-10T08:13:04.382Z"},"accession":"S-EPMC9669535","cross_references":{"pubmed":["36397128"],"doi":["10.1186/s13098-022-00951-5"]}}